Complicated urinary tract infection (UTI) is associated
with a condition [eg structural or functional abnormalities of the genitourinary tract (GUT)] or the presence of an underlying disease that interferes with host defense mechanisms, which increases the risks of acquiring infection, failing therapy or having recurrent infections. The successful treatment of a complicated UTI considers effective antimicrobial therapy, optimal management of the underlying abnormalities or other diseases and adequate life-supporting measures.
New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Local oestrogen preparations may safely and effectively reduce the number of recurrent urinary tract infections (rUTIs) in with genitourinary syndrome of menopause (GSM), delivering symptomatic relief and hence improving quality of life, according to a review.
Pregnant women with urinary tract infections (UTIs) caused by multidrug-resistant (MDR) bacteria may be at increased risk of developing pyelonephritis, according to a single-centre, retrospective study presented at SMFM 2020.
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.